- info@anseaconsulting.com
- Singapore: +65 6956 6164
- Basel: +41 61 564 1420
Conduct a comprehensive analog analysis across the UK, France and Germany to understand how recently launched therapies in chronic, GP-prescribed, mass-market disease areas achieved pricing and reimbursement outcomes, and identify learnings relevant to future market entry.
Identified and shortlisted relevant analogs, with a focus on newer therapeutic classes and products competing against established generic treatments. Assessed reimbursement decisions from NICE, SMC, HAS and G-BA/IQWiG, including sponsor-selected comparators, clinical trials considered, reimbursement outcomes and pricing versus generic alternatives.
Comprehensive EU Analog Analysis report covering selected analogs, pricing and reimbursement positioning, HTA assessment outcomes, comparator and clinical trial strategies, price premiums versus generic alternatives, and cross-market learnings across the three markets.
Provided evidence-based benchmarks for pricing and reimbursement strategy, enabling the client to understand how comparable therapies were assessed by European HTA bodies, the pricing premium achieved over generics, and the key factors that could influence the market potential and access strategy of a similar product.
